Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Snehal Naik"'
Autor:
null Neel Snehal Naik, null Dr Kantilal Narkhede, null Dr Anuradha Prajapati, null Dr Sachin Narkhede
Publikováno v:
EPRA International Journal of Research & Development (IJRD). :140-145
The majority of cancer treatments used today focus on surgically removing the tumour mass. The rapid proliferation of malignant cells is significantly slowed down by physical and chemical therapies like radiotherapy and chemotherapy. Additionally, th
Purpose: The Wnt/β-catenin (β-cat) signaling cascade is a key regulator of development, and dysregulation of Wnt/β-cat contributes to selected cancers, such as colorectal, breast, and hepatocellular carcinoma, through abnormal activation of Wnt ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3ec7de44d87f4201f7e95e46af9156
https://doi.org/10.1158/1078-0432.c.6517618.v1
https://doi.org/10.1158/1078-0432.c.6517618.v1
CCR Translation for the Article from Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abb02e31a1e1e3c3451ba351f422b05
https://doi.org/10.1158/1078-0432.22440268
https://doi.org/10.1158/1078-0432.22440268
Supplementary Data from Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::188ef7b5630085c296a3ef0326e769ff
https://doi.org/10.1158/1078-0432.22440265
https://doi.org/10.1158/1078-0432.22440265
Publikováno v:
Cell and Gene Therapy Insights.
Autor:
Laurent Peyrin-Biroulet, Scott D. Lee, Preston Klassen, Severine Vermeire, Bruce R. Yacyshyn, T Kühbacher, Michael Chiorean, Christopher H Cabell, Jinkun Zhang, Snehal Naik, Julián Panés, William J. Sandborn
Publikováno v:
Gastroenterology. 158:550-561
BACKGROUND & AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely
Publikováno v:
MedPulse International Journal of Gynaecology. 13:25-30
Autor:
G Akhundova-Unadkat, L Peyrin-Biroulet, Severine Vermeire, Bruce E. Sands, Michael Chiorean, CJ Rabbat, J Panés, S W Schreiber, Snehal Naik, W J Sandborn
Publikováno v:
Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV).
Autor:
Caroline Fox, Anjali Jain, Bayda Bahur, Ezra Chefitz, Marla Dubinsky, Alexandra Bruss, Andres Yarur, Poonam Beniwal-Patel, Kanika Kamal, Snehal Naik, Daniel J. Stein, Ryan C. Ungaro, Amir Patel, Jacqueline Jossen, Priya Sehgal, Becky L. Phan
Publikováno v:
J Crohns Colitis
Background and Aims Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn’s disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission. Methods We performed a cross-sec
Autor:
Stefan Schreiber, Christopher Rabbat, Laurent Peyrin-Biroulet, Snehal Naik, Bruce E. Sands, Severine Vermeire, Michael V. Chiorean, William J. Sandborn, Julián Panés, Gamar Akhundova-Unadkat
Publikováno v:
American Journal of Gastroenterology. 116:S325-S326